Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Galajda

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Diabetes Research and Clinical Practice|May 23, 2008
Prevalence of diabetes mellitus and metabolic syndrome in SlovakiaMarián Mokán, Peter Galajda, Dana Prídavková, et al.
Drugs & Aging|May 9, 2018
Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing ExperiencesTomáš Bolek, Matej Samoš, Ingrid Škorňová, et al.
Journal of Diabetes Research|January 30, 2016
Type 2 Diabetes and ADP Receptor Blocker TherapyMatej Samoš, Marián Fedor, František Kovář, et al.
BMC Biology|November 29, 2022
Ecological succession and the competition-colonization trade-off in microbial communitiesMiles T Wetherington, Krisztina Nagy, László Dér, et al.
Plos One|October 30, 2013
Spatial structure facilitates cooperation in a social dilemma: empirical evidence from a bacterial communityFelix J H Hol, Peter Galajda, Krisztina Nagy, et al.
Journal of Cardiovascular Pharmacology|May 9, 2018
Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs: Should We Worry About Thrombosis?Tomáš Bolek, Matej Samoš, Ingrid Škorňová, et al.
Journal of Diabetes Research|March 17, 2022
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current PharmacotherapyJakub Benko, Matej Samoš, Tomáš Bolek, et al.
American Journal of Therapeutics|April 29, 2017
The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial FibrillationTomáš Bolek, Matej Samoš, Lucia Stančiaková, et al.
International Journal of Endocrinology|January 20, 2016
The Intricate Network of Adipokines and StrokeEma Kantorová, Ľubica Jesenská, Daniel Čierny, et al.
Pharmacology Research & Perspectives|May 13, 2021
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?Ingrid Škorňová, Matej Samoš, Tomáš Bolek, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Diabetes Research and Clinical Practice|May 23, 2008
Prevalence of diabetes mellitus and metabolic syndrome in SlovakiaMarián Mokán, Peter Galajda, Dana Prídavková, et al.
Drugs & Aging|May 9, 2018
Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing ExperiencesTomáš Bolek, Matej Samoš, Ingrid Škorňová, et al.
Journal of Diabetes Research|January 30, 2016
Type 2 Diabetes and ADP Receptor Blocker TherapyMatej Samoš, Marián Fedor, František Kovář, et al.
BMC Biology|November 29, 2022
Ecological succession and the competition-colonization trade-off in microbial communitiesMiles T Wetherington, Krisztina Nagy, László Dér, et al.
Plos One|October 30, 2013
Spatial structure facilitates cooperation in a social dilemma: empirical evidence from a bacterial communityFelix J H Hol, Peter Galajda, Krisztina Nagy, et al.
Journal of Cardiovascular Pharmacology|May 9, 2018
Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs: Should We Worry About Thrombosis?Tomáš Bolek, Matej Samoš, Ingrid Škorňová, et al.
Journal of Diabetes Research|March 17, 2022
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current PharmacotherapyJakub Benko, Matej Samoš, Tomáš Bolek, et al.
American Journal of Therapeutics|April 29, 2017
The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial FibrillationTomáš Bolek, Matej Samoš, Lucia Stančiaková, et al.
International Journal of Endocrinology|January 20, 2016
The Intricate Network of Adipokines and StrokeEma Kantorová, Ľubica Jesenská, Daniel Čierny, et al.
Pharmacology Research & Perspectives|May 13, 2021
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?Ingrid Škorňová, Matej Samoš, Tomáš Bolek, et al.
Pageof 8